Bioanalytical Testing Services Market Size, Growth by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) - Global Forecasts to 2027
The global Bioanalytical Testing Services Market in terms of revenue was estimated to be worth $2.9 billion in 2022 and is poised to reach $6.0 billion by 2027, growing at a CAGR of 15.6% from 2022 to 2027. The major factors influencing the growth of the market includes the well-established pharmaceutical industry, strong presence of major service providers, large number of ongoing clinical trial studies, high R&D expenditure, growth in the biosimilars and generics markets, and the rise in the outsourcing of preclinical, clinical, and laboratory testing services by pharmaceutical and biopharmaceutical companies in the region.
To know about the assumptions considered for the study, Request for Free Sample Report
Bioanalytical Testing Services Market Dynamics
Drivers: Rising focus on the analytical testing of biologics and biosimilars
Biologics represent one of the most promising new therapeutic areas and are becoming increasingly important in the pharmaceutical market; around 800 products are in the pipeline at present. One of the key reasons for this is the rising prevalence of chronic diseases. However, considering the high cost of biologics and the rising focus of various governments on reducing healthcare costs, the focus on biosimilars has increased in recent years. The impending expiry of the patents and exclusivity periods of biologics have also created opportunities for the development of follow-on biologics or biosimilars. According to GaBi, twelve biologics, with global sales of more than USD 67 billion, are scheduled to go off-patent in major markets by 2020, with more biologics likely to follow.
The expected rise in biosimilar R&D will bring with it a growing demand for the associated bioanalytical testing services—compatibility studies for biosimilars, stability testing, product release testing, and protein analysis of biosimilars—to reduce the risks associated with drug development. Moreover, the introduction of biosimilars and the move toward continuous processing are creating the need for more rapid and sensitive analytical techniques.
Increasing preference for outsourcing analytical testing
Pharmaceutical companies have begun outsourcing several R&D functions that are not core to their internal structure. Companies are trying to be more efficient in the drug development process by focusing on their internal core competencies to bring new products to the market in a more cost-effective manner. Cost reductions, efficiency increases, and optimal staffing are some of the key advantages driving the outsourcing of bioanalytical testing for large companies.
In the pharmaceutical sector, the analytical and testing services were the most-outsourced services, followed by solid-dosage form manufacturing, injectable manufacturing, clinical trials, formulation development, and R&D. This trend is backed by an increase in the numbers, capabilities, and volumes of contract research organization and the liking for specific providers over the long-term as opposed to short-term contracts. In the following years, outsourcing as a strategy is anticipated to gain greater notoriety. When coupled with the growth in biologic and biosimilar R&D, this factor is projected to create a very favorable environment for market development.
The outsourcing of bioanalytical testing services supports pharmaceutical companies lessen risks by avoiding large funds in purchasing analytical equipment and maintaining manpower, particularly when development efforts are in the initial stages. The accessibility of specialized analytical testing service providers with key capabilities to deliver optimal results rapidly has led to growing consideration among pharmaceutical businesses to outsource testing services to third-party service providers.
Growing R&D expenditure in the pharmaceutical and biopharmaceutical industry
Pharmaceutical and biotechnology companies invest heavily in research to come up with breakthrough molecules. The increasing prevalence of infectious and chronic diseases has led to significant investments in the development of new drugs and vaccines among key pharmaceutical companies such as Novartis, Takeda, Sanofi, Eli Lilly, and Pfizer.
Moreover, the outbreak of the COVID-19 pandemic has increased the focus among pharmaceutical and biopharmaceutical companies to develop effective drugs and vaccines against viral infections. In this scenario, establishing effective workflows and processes to reduce the time and costs involved in drug and vaccine development has gained significance. This, in turn, is favoring the outsourcing of bioanalytical testing to specialized service providers.
Rising adoption of the Quality by Design approach
Pharmaceutical companies are progressively adopting the Quality-by-Design (QbD) concept promoted by regulatory agencies such as the EMA and US FDA across the globe to improve the robustness of their manufacturing processes and enhance product quality and manufacturing productivity. The QbD approach in the pharmaceutical industry has evolved over the years with the issuance of ICH Q8 (R2) (Pharmaceutical Development), ICH Q9 (Quality Risk Management), and ICH Q10 (Pharmaceutical Quality System).
QbD ensures product quality and requires process performance characteristics to be scientifically designed to meet specific objectives, not merely empirically derived from the performance of test batches. After recommendations from the FDA in 2013, generic drug manufacturers are also adopting the QbD approach in manufacturing operations.
According to the ICH Q 10 guidelines, analytical methods are a key part of the pharmaceutical quality system. Implementation of analytical QbD (AQbD) in the manufacturing process ensures product quality and performance. There is a huge difference between the traditional and AQbD approaches of analytical method development. The traditional approach does not use statistical calculations and risk assessment, while the AQbD approach utilizes tools such as CQA, ATP, DoE, and risk assessment, which helps to easily identify the risk initially so that quality can be improved.
Furthermore, a rising number of conferences, symposia, workshops, and training courses, especially in emerging countries, have played a crucial role in creating awareness about the benefits of adopting the QbD approach among pharmaceutical and biopharmaceutical manufacturers and research organizations. The increasing acceptance and adoption of the QbD approach among pharmaceutical and biopharmaceutical companies across the globe are expected to play a key role in the growth of the bioanalytical testing services market in the coming years.
Restraints: Dearth of skilled professionals
The shortage of skilled professionals to handle advanced equipment required for bioanalytical tests is a major factor that is expected to restrain the growth of this market. The US Bureau of Labor Statistics estimated that there would be 18,580 clinical laboratory science (CLS) program vacancies in the country by 2020. However, only 5,000 students graduate from accredited CLS programs each year. This means that educational programs are delivering less than a third of the trained professionals needed. This may hamper the adoption of new technologies and methodologies, thereby limiting the growth of the bioanalytical testing services market in the coming years.
Pricing pressure faced by major players
The bioanalytical testing services market is highly competitive and is expected to grow rapidly in the coming years due to the increasing number of bioanalytical CROs. Additionally, the growing number of contract development and manufacturing organizations (CDMOs) offering bioanalytical services is further expected to intensify the competition in the market. Over the last few years, the number of bioanalytical testing service providers has increased in emerging markets, such as China, India, and Brazil, which is a major challenge for global players. These local or regional analytical testing service providers offer services at lower prices as compared to established bioanalytical testing service providers, thereby increasing the pricing pressure on global players to a certain extent. This is adversely affecting the profit margins of global players, especially in emerging markets. Currently, several global players are focusing on entering into agreements, acquisitions, and collaborations to overcome this challenge, maintain their positions in the global market, and establish a stronghold in local markets characterized by low-priced services. However, the threat of local players will continue to affect the pricing policies of global players in the coming years.
Opportunities: Emerging countries in the Asia Pacific region
Emerging markets present significant growth opportunities for providers of healthcare analytical testing services—particularly India and China. Governments in both countries are extensively emphasizing the development of life science infrastructure by undertaking several projects and initiatives to encourage pharmaceutical and biopharmaceutical companies to develop and manufacture drugs for various infectious and chronic diseases.
According to a report from the Indian Pharmaceutical Alliance (IPA), the Indian pharmaceutical industry was growing at a rate of 7–8% and is estimated to register USD 80–90 billion in annual revenue by 2030. Nevertheless, with the support of the government and regulatory bodies, the industry can expand at a pace of 11–12%. The support from government in the form of regulatory assistance and investments is integral step toward the commencement of innovation-led industry growth. Furthermore, the favorable government scenario has helped start-ups by providing them soft loans for pharma industrial R&D projects and a grant-in-aid for clinical trials for creating drugs for neglected diseases.
Besides this, the government is also offering non-fiscal benefits such as backing in research in all systems of medicines, involving setting up facilities and joint research projects for industries and institutions.
Furthermore, in 2020, the Chinese State Drug Administration (SDA) opened up a large market for bioanalytical CROs across the world by allowing Chinese pharmaceutical companies to use clinical trial data from studies conducted outside China for their drug submissions to the SDA. This encouraged global CROs keen to enter the growing Chinese market for pharmaceutical drug testing to expand their Chinese facilities and provide bioanalytical services to pharmaceutical and biotechnology companies.
Rising demand for specialized bioanalytical testing services
Traditionally, pharmaceutical and biopharmaceutical companies outsourced only late-phase drug development and routine processes to analytical testing service providers and conducted the early-phase method development projects and problem-solving activities in-house. However, in recent years, they are increasingly outsourcing testing services much earlier in the product development cycle to focus on their core strengths. Pharmaceutical companies choose to outsource services to CROs mainly to gain access to innovative technologies that accelerate the development of compounds through the product pipeline. For instance, companies such as Pfizer, Merck, and Roche have reduced their in-house testing services to fuel their R&D pipelines to meet the growing demand for new drug molecules for various therapeutic areas.
Currently, many pharmaceutical and biopharmaceutical companies are focusing on building a diverse product portfolio and developing new small and large molecules. Combination products, delivery devices, and reformulated or re-engineered drugs are being developed by companies to cater to the unmet needs in the market.
Pharmaceutical companies are focusing on various specialized testing services such as Liquid Chromatography-Mass Spectrometry (LC/MS), gene expression analysis, wet chemistry analysis of compendia raw materials, and trace metal analysis with Inductively Coupled Mass Spectrometry (ICP-MS). These tests require high-end equipment and skilled professionals. To save equipment and labor costs, pharmaceutical and biopharmaceutical companies prefer to outsource these specialized testing services to CROs.
Challenges: Innovative formulations demanding a unique bioanalytical testing approach
Over the years, competition in the pharmaceutical and biopharmaceutical market to develop cutting-edge therapies and gain the edge of patent exclusivity by quick drug development has increased significantly. In all phases of pharmaceutical and biopharmaceutical development, bioanalytical testing plays a major role and is the most outsourced process among all the chemistry, manufacturing, and control (CMC) activities. CMC data is also pivotal to meet regulatory expectations and acquire Investigational New Drug (IND) approval.
Diversity of CMC requirements for biopharmaceutical IND and the development of novel drug delivery systems pose a variety of challenges and require a myriad of analytical methods for testing new drug molecules. Currently, several service providers are also enhancing their portfolios of service offerings in line with the demand from the pharmaceutical and biopharmaceutical industries. However, they must still keep pace with the current rate of technological changes.
Growing need to improve the sensitivity of bioanalytical methods
One of the prominent challenges in this field is ensuring sufficient sensitivity, speed of analysis, and robustness of methodologies. Changes, fluctuations, and variations in end-user demands and regulatory requirements make it highly difficult for service providers to ensure sufficient testing capabilities; they must constantly look for and implement innovative and new assays. For instance, the evaluation of the placental transfer of certolizumab pegol (CZP) requires highly sensitive and selective bioanalytical assays to measure low CZP concentrations in infant and umbilical cord blood. For this study, the electrochemiluminescence immunoassay was validated for measuring low CZP concentrations in human plasma.
Similarly, there are many challenges faced when optimizing bioassays for biologics that increase timelines and exceed budgets, ending in results that do not satisfy requirements. The reason behind this is early in the process of assay development for biologics, there is limited production experience and incomplete knowledge about assay capabilities. In recent years, innovative assay formats such as reporter gene and second messenger assays have been emerging in drug discovery, and some of these assays have been tried in cell-based assays for drug development as well. However, it is becoming a challenge for service providers, as they have to constantly seek newer sensitive assays to cater to the changing demands of end users.
The cell-based assays accounted for the largest share of the bioanalytical testing services market
The cell-based assays segment dominated the market. The increasing prevalence of chronic diseases and the rising number of clinical trials are expected to drive the segment growth.
The Oncology segment dominated this market with the largest share
The oncology accounted for the largest share of the global bioanalytical testing services market. and is also expected to grow at the highest CAGR. Surging number of clinical trials conducted for cancer is driving the segment growth.
The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the bioanalytical testing services market
The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the global market. Pharmaceutical and biopharmaceutical companies mainly focus on developing new drugs for the treatment of various diseases. Increased outsourcing of early-phase development, clinical, and laboratory testing services by pharmaceutical companies is expected to drive the segment growth.
Asia Pacific to grow at the fastest CAGR during the forecast period
The APAC market is becoming a key destination for drug development and clinical research. Increase in the number of clinical trial activities in the region is mainly due to reasons such as cost benefits, a large treatment-naïve population, maintenance of participants in clinical trials, and constantly improving regulatory procedures.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the Bioanalytical testing services market: Charles River (US), Medpace (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), IQVIA (US), SGS SA (Switzerland), Laboratory Corporation of America Holdings (US), Intertek Group (UK), Syneos Health (US), ICON (Ireland), Frontage Labs (US), PPD (US), PAREXEL International Corporation (US), Almac Group (UK), Celerion (US), Altasciences (US), BioAgilytix Labs (US), Lotus Labs (India), LGS Limited (UK), Sartorius AG (Germany), CD BioSciences (US), Absorption Systems LLC (US), Pace Analytical Services (US), Bioneeds India Private Limited (India) and Vipragen Biosciences (India).
Bioanalytical Testing Services Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$2.9 billion |
|
Estimated Value by 2027 |
$6.0 billion |
|
Growth Rate |
poised to grow at a CAGR of 15.6% |
|
Largest Share Segments |
Cell-based Assays, Oncology & Pharmaceutical and Biopharmaceutical Companies |
|
Market Report Segmentation |
Type, Application, End User & Region |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
Report categorizes the global bioanalytical testing services market into the following segments and subsegments:
By Type
- Cell-based Assays
- Bacterial cell-based assays
- Viral cell-based assays
- Virology Testing
- In Vitro Virology Testing
- In Vivo Virology Testing
- Species-specific Viral PCR Assays
- Method Development, Optimization, and Validation
- Serology, Immunogenicity, and Neutralizing Antibodies
- Biomarker Testing
- Pharmacokinetic Testing
- Other Services
By Application
- Oncology
- Neurology
- Infectious Diseases
- Gastroenterology
- Cardiology
- Other Applications
By End User
- Pharmaceutical and Biopharmaceutical Companies
- Contract Development and Manufacturing Organizations
- Contract Research Organizations
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Latin America
- Middle East & Africa
Frequently Asked Questions (FAQ):
What is the size of Bioanalytical Testing Services Market ?
The Bioanalytical Testing Services Market size is projected to reach USD 6.0 Billion by 2027, growing at a CAGR of 15.6%.
Why is Bioanalytical Testing Services Market Growing?
Factors such as the rising focus on the analytical testing of biologics and biosimilars, increasing preference for outsourcing analytical testing, growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, and the rising adoption of the Quality by Design approach are expected to drive the growth of this market during the forecast period. However, the dearth of skilled professionals is a major factor that is expected to restrain the growth of this market in the coming years.
Who all are the prominent players of Bioanalytical Testing Services Market ?
Prominent players in the bioanalytical testing services market include Charles River (US), Medpace (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), IQVIA (US), SGS SA (Switzerland), Laboratory Corporation of America Holdings (US), Intertek Group (UK), Syneos Health (US), ICON (Ireland), Frontage Labs (US), PPD (US), PAREXEL International Corporation (US), Almac Group (UK), Celerion (US), Altasciences (US), BioAgilytix Labs (US), Lotus Labs (India), LGS Limited (UK), Sartorius AG (Germany), CD BioSciences (US), Absorption Systems LLC (US), Pace Analytical Services (US), Bioneeds India Private Limited (India) and Vipragen Biosciences (India).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 25)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION & SCOPE
1.2.1 MARKETS COVERED
FIGURE 1 BIOANALYTICAL TESTING SERVICES MARKET SEGMENTATION
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 MARKET RANKING ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 36)
FIGURE 7 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027
FIGURE 8 MARKET, BY APPLICATION, 2022 VS. 2027
FIGURE 9 MARKET, BY END USER, 2022 VS. 2027
FIGURE 10 MARKET: REGIONAL SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 39)
4.1 MARKET OVERVIEW
FIGURE 11 RISING FOCUS ON ANALYTICAL TESTING OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET, BY APPLICATION & COUNTRY (2021)
FIGURE 12 ONCOLOGY SEGMENT TO DOMINATE ASIA PACIFIC MARKET IN 2021
4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 13 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 REGIONAL MIX: MARKET
FIGURE 14 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 MARKET: DEVELOPING VS. DEVELOPED COUNTRIES
FIGURE 15 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising focus on the analytical testing of biologics and biosimilars
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
5.2.1.2 Increasing preference for outsourcing analytical testing
5.2.1.3 Growing R&D expenditure in the pharmaceutical and biopharmaceutical industry
FIGURE 17 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2017–2024
5.2.1.4 Rising adoption of the Quality by Design approach
5.2.2 RESTRAINTS
5.2.2.1 Dearth of skilled professionals
5.2.2.2 Pricing pressure faced by major players
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging countries in the Asia Pacific region
5.2.3.2 Rising demand for specialized bioanalytical testing services
5.2.4 CHALLENGES
5.2.4.1 Innovative formulations demanding a unique bioanalytical testing approach
5.2.4.2 Growing need to improve the sensitivity of bioanalytical methods
5.3 ASSESSMENT OF COVID-19 IMPACT ON THE ECONOMIC SCENARIO IN THE BIOANALYTICAL TESTING SERVICES MARKET
6 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE (Page No. - 50)
6.1 INTRODUCTION
TABLE 3 MARKET, BY TYPE, 2020–2027
6.2 CELL-BASED ASSAYS
TABLE 4 MARKET FOR CELL-BASED ASSAYS, BY TYPE, 2020–2027
TABLE 5 MARKET FOR CELL-BASED ASSAYS, BY COUNTRY, 2020–2027
6.2.1 BACTERIAL CELL-BASED ASSAYS
6.2.1.1 Bacterial cell-based assays dominate the bioanalytical testing services market for cell-based assays
TABLE 6 MARKET FOR BACTERIAL CELL-BASED ASSAYS, BY COUNTRY, 2020–2027
6.2.2 VIRAL CELL-BASED ASSAYS
6.2.2.1 Increasing outbreaks of viral diseases to support the growth of this market segment
TABLE 7 MARKET FOR VIRAL CELL-BASED ASSAYS, BY COUNTRY, 2020–2027
6.3 VIROLOGY TESTING
TABLE 8 MARKET FOR VIROLOGY TESTING, BY TYPE, 2020–2027
TABLE 9 MARKET FOR VIROLOGY TESTING, BY COUNTRY, 2020–2027
6.3.1 IN VITRO VIROLOGY TESTING
6.3.1.1 Higher uptake of in vitro virology assays in the development of anti-viral pharmaceuticals to drive the growth of this market segment
TABLE 10 MARKET FOR IN VITRO VIROLOGY TESTING, BY COUNTRY, 2020–2027
6.3.2 IN VIVO VIROLOGY TESTING
6.3.2.1 High utilization of in vivo assays during important production phases to drive their demand
TABLE 11 BIOANALYTICAL TESTING SERVICES MARKET FOR IN VIVO VIROLOGY TESTING, BY COUNTRY, 2020–2027
6.3.3 SPECIES-SPECIFIC VIRAL PCR ASSAYS
6.3.3.1 Wide application of species-specific viral PCR assays in the detection of viral risks to support the growth of this market segment
TABLE 12 BIOANALYTICAL TESTING SERVICES MARKET FOR SPECIES-SPECIFIC VIRAL PCR ASSAYS, BY COUNTRY, 2020–2027
6.4 METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION
6.4.1 MANDATORY REQUIREMENT BY REGULATORY AUTHORITIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 13 MARKET FOR METHOD DEVELOPMENT OPTIMIZATION AND VALIDATION, BY COUNTRY, 2020–2027
6.5 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES
6.5.1 INCREASING APPLICATIONS OF SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 14 MARKET FOR SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES, BY COUNTRY, 2020–2027
6.6 BIOMARKER TESTING
6.6.1 GROWING EMPHASIS ON THE DEVELOPMENT OF PERSONALIZED MEDICINES TO DRIVE THE DEMAND FOR BIOMARKER TESTING SERVICES
TABLE 15 BIOANALYTICAL TESTING SERVICES MARKET FOR BIOMARKER TESTING, BY COUNTRY, 2020–2027
6.7 PHARMACOKINETIC TESTING
6.7.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE THE DEMAND FOR PHARMACOKINETIC TESTING SERVICES
TABLE 16 MARKET FOR PHARMACOKINETIC TESTING, BY COUNTRY, 2020–2027
6.8 OTHER SERVICES
TABLE 17 BIOANALYTICAL TESTING SERVICES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027
7 BIOANALYTICAL TESTING SERVICES MARKET, BY APPLICATION (Page No. - 66)
7.1 INTRODUCTION
TABLE 18 MARKET, BY APPLICATION, 2020–2027
7.2 ONCOLOGY
7.2.1 ONCOLOGY IS THE LARGEST APPLICATION SEGMENT IN THE BIOANALYTICAL TESTING SERVICES MARKET
FIGURE 18 WORLDWIDE CANCER INCIDENCE AND MORTALITY (2018–2040)
TABLE 19 BIOANALYTICAL TESTING SERVICES MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027
7.3 NEUROLOGY
7.3.1 ROBUST PIPELINE OF DRUGS FOR CNS DISEASES TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 20 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 21 BIOANALYTICAL TESTING SERVICES MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027
7.4 INFECTIOUS DISEASES
7.4.1 OUTBREAK OF COVID-19 TO BOOST THE GROWTH OF THIS MARKET SEGMENT
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027
7.5 GASTROENTEROLOGY
7.5.1 RISING PREVALENCE OF CHRONIC DIGESTIVE DISORDERS TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET FOR GASTROENTEROLOGY APPLICATIONS, BY COUNTRY, 2020–2027
7.6 CARDIOLOGY
7.6.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
TABLE 24 BIOANALYTICAL TESTING SERVICES MARKET FOR CARDIOLOGY APPLICATIONS, BY COUNTRY, 2020–2027
7.7 OTHER APPLICATIONS
TABLE 25 MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027
8 BIOANALYTICAL TESTING SERVICES MARKET, BY END USER (Page No. - 76)
8.1 INTRODUCTION
TABLE 26 MARKET, BY END USER, 2020–2027
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
8.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ARE THE LARGEST END USERS OF BIOANALYTICAL TESTING SERVICES
FIGURE 19 PHARMACEUTICAL R&D SPENDING, 2010–2024
TABLE 27 BIOANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027
8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
8.3.1 CDMOS PROVIDE SERVICES SUCH AS ANALYTICAL DEVELOPMENT, FORMULATION SCREENING AND DEVELOPMENT, STABILITY STUDIES, AND PRE-CLINICAL SAFETY ASSESSMENT STUDIES
TABLE 28 BIOANALYTICAL TESTING SERVICES MARKET FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2020–2027
8.4 CONTRACT RESEARCH ORGANIZATIONS
8.4.1 CONTRACT RESEARCH ORGANIZATIONS ARE INCREASINGLY SUBCONTRACTING THEIR ACTIVITIES TO NICHE LABORATORIES SPECIALIZED IN PROVIDING BIOANALYTICAL TESTING SERVICES
TABLE 29 BIOANALYTICAL TESTING SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027
9 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION (Page No. - 82)
9.1 INTRODUCTION
FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 30 MARKET, BY REGION, 2020–2027
9.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: MARKET SNAPSHOT
TABLE 31 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027
TABLE 32 NORTH AMERICA: MARKET, BY TYPE, 2020–2027
TABLE 33 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 34 NORTH AMERICA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 35 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027
TABLE 36 NORTH AMERICA: MARKET, BY END USER, 2020–2027
9.2.1 US
9.2.1.1 US is largest market for bioanalytical testing services in North America
TABLE 37 US: KEY INDICATORS
TABLE 38 US: MARKET, BY TYPE, 2020–2027
TABLE 39 US: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 40 US: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 41 US: MARKET, BY APPLICATION, 2020–2027
TABLE 42 US: MARKET, BY END USER, 2020–2027
9.2.2 CANADA
9.2.2.1 Increasing number of clinical trials in Canada to support market growth
TABLE 43 CANADA: KEY INDICATORS:
TABLE 44 CANADA: MARKET, BY TYPE, 2020–2027
TABLE 45 CANADA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 46 CANADA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 47 CANADA: MARKET, BY APPLICATION, 2020–2027
TABLE 48 CANADA: MARKET, BY END USER, 2020–2027
9.3 EUROPE
TABLE 49 EUROPE: MARKET, BY COUNTRY, 2020–2027
TABLE 50 EUROPE: MARKET, BY TYPE, 2020–2027
TABLE 51 EUROPE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 52 EUROPE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 53 EUROPE: MARKET, BY APPLICATION, 2020–2027
TABLE 54 EUROPE: MARKET, BY END USER, 2020–2027
9.3.1 GERMANY
9.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
TABLE 55 GERMANY: KEY INDICATORS
TABLE 56 GERMANY: MARKET, BY TYPE, 2020–2027
TABLE 57 GERMANY: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 58 GERMANY: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 59 GERMANY: MARKET, BY APPLICATION, 2020–2027
TABLE 60 GERMANY: MARKET, BY END USER, 2020–2027
9.3.2 FRANCE
9.3.2.1 High number of oncology clinical trials in France to drive market growth
TABLE 61 FRANCE: KEY INDICATORS
TABLE 62 FRANCE: MARKET, BY TYPE, 2020–2027
TABLE 63 FRANCE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 64 FRANCE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 65 FRANCE: MARKET, BY APPLICATION, 2020–2027
TABLE 66 FRANCE: MARKET, BY END USER, 2020–2027
9.3.3 UK
9.3.3.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth
TABLE 67 UK: KEY INDICATORS
TABLE 68 UK: MARKET, BY TYPE, 2020–2027
TABLE 69 UK: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 70 UK: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 71 UK: MARKET, BY APPLICATION, 2020–2027
TABLE 72 UK: MARKET, BY END USER, 2020–2027
9.3.4 ITALY
9.3.4.1 Low drug approval time in Italy, along with the growing number of clinical trials, to drive market growth
TABLE 73 ITALY: KEY INDICATORS
TABLE 74 ITALY: MARKET, BY TYPE, 2020–2027
TABLE 75 ITALY: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 76 ITALY: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 77 ITALY: MARKET, BY APPLICATION, 2020–2027
TABLE 78 ITALY: MARKET, BY END USER, 2020–2027
9.3.5 SPAIN
9.3.5.1 Rising R&D expenditure to boost market growth
TABLE 79 SPAIN: KEY INDICATORS
TABLE 80 SPAIN: MARKET, BY TYPE, 2020–2027
TABLE 81 SPAIN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 82 SPAIN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 83 SPAIN: MARKET, BY APPLICATION, 2020–2027
TABLE 84 SPAIN: MARKET, BY END USER, 2020–2027
9.3.6 REST OF EUROPE
TABLE 85 ROE: MARKET, BY TYPE, 2020–2027
TABLE 86 ROE: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 87 ROE: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 88 ROE: MARKET, BY APPLICATION, 2020–2027
TABLE 89 ROE: MARKET, BY END USER, 2020–2027
9.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 90 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027
TABLE 91 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027
TABLE 92 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 93 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 94 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027
TABLE 95 ASIA PACIFIC: MARKET, BY END USER, 2020–2027
9.4.1 CHINA
9.4.1.1 China is largest market for bioanalytical testing services in Asia Pacific
TABLE 96 CHINA: KEY INDICATORS
TABLE 97 CHINA: MARKET, BY TYPE, 2020–2027
TABLE 98 CHINA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 99 CHINA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 100 CHINA: MARKET, BY APPLICATION, 2020–2027
TABLE 101 CHINA: MARKET, BY END USER, 2020–2027
9.4.2 JAPAN
9.4.2.1 Rising geriatric population to drive market growth in Japan
TABLE 102 JAPAN: KEY INDICATORS
TABLE 103 JAPAN: MARKET, BY TYPE, 2020–2027
TABLE 104 JAPAN: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 105 JAPAN: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 106 JAPAN: MARKET, BY APPLICATION, 2020–2027
TABLE 107 JAPAN: MARKET, BY END USER, 2020–2027
9.4.3 INDIA
9.4.3.1 Growing pharmaceutical industry in India to drive market growth
TABLE 108 INDIA: KEY INDICATORS
TABLE 109 INDIA: MARKET, BY TYPE, 2020–2027
TABLE 110 INDIA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 111 INDIA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 112 INDIA: MARKET, BY APPLICATION, 2020–2027
TABLE 113 INDIA: MARKET, BY END USER, 2020–2027
9.4.4 REST OF ASIA PACIFIC
TABLE 114 ROAPAC: MARKET, BY TYPE, 2020–2027
TABLE 115 ROAPAC: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 116 ROAPAC: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 117 ROAPAC: MARKET, BY APPLICATION, 2020–2027
TABLE 118 ROAPAC: MARKET, BY END USER, 2020–2027
9.5 LATIN AMERICA
9.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH
TABLE 119 LATIN AMERICA: MARKET, BY TYPE, 2020–2027
TABLE 120 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 121 LATIN AMERICA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 122 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027
TABLE 123 LATIN AMERICA: MARKET, BY END USER, 2020–2027
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
TABLE 124 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2020–2027
TABLE 125 MIDDLE EAST & AFRICA: CELL-BASED ASSAYS MARKET, BY TYPE, 2020–2027
TABLE 126 MIDDLE EAST & AFRICA: VIROLOGY TESTING MARKET, BY TYPE, 2020–2027
TABLE 127 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027
TABLE 128 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027
10 COMPETITIVE LANDSCAPE (Page No. - 132)
10.1 INTRODUCTION
FIGURE 23 KEY DEVELOPMENTS IN BIOANALYTICAL TESTING SERVICES MARKET
10.2 COMPETITIVE LEADERSHIP MAPPING
10.2.1 STARS
10.2.2 EMERGING LEADERS
10.2.3 PERVASIVE PLAYERS
10.2.4 PARTICIPANTS
FIGURE 24 BIOANALYTICAL TESTING SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.3 BIOANALYTICAL TESTING SERVICES MARKET SHARE ANALYSIS
FIGURE 25 MARKET SHARE ANALYSIS: MARKET (2021)
10.4 BIOANALYTICAL TESTING SERVICES MARKET: GEOGRAPHICAL ASSESSMENT
FIGURE 26 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN BIOANALYTICAL TESTING SERVICES MARKET (2021)
10.5 COMPETITIVE SITUATIONS & TRENDS
10.5.1 PRODUCT LAUNCHES (2020–2022)
10.5.2 EXPANSIONS (2020–2022)
10.5.3 DEALS (2020–2022)
11 COMPANY PROFILES (Page No. - 139)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 CHARLES RIVER
TABLE 129 CHARLES RIVER: BUSINESS OVERVIEW
FIGURE 27 CHARLES RIVER: COMPANY SNAPSHOT (2021)
11.2 MEDPACE HOLDINGS
TABLE 130 MEDPACE HOLDINGS: BUSINESS OVERVIEW
FIGURE 28 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2021)
11.3 WUXI APPTEC
TABLE 131 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 29 WUXI APPTEC: COMPANY SNAPSHOT (2021)
11.4 EUROFINS SCIENTIFIC
TABLE 132 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 30 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
11.5 IQVIA INC.
TABLE 133 IQVIA: BUSINESS OVERVIEW
FIGURE 31 IQVIA: COMPANY SNAPSHOT (2021)
11.6 SGS SA
TABLE 134 SGS SA: BUSINESS OVERVIEW
FIGURE 32 SGS SA: COMPANY SNAPSHOT (2021)
11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 135 LABCORP: BUSINESS OVERVIEW
FIGURE 33 LABCORP: COMPANY SNAPSHOT (2021)
11.8 INTERTEK GROUP PLC
TABLE 136 INTERTEK GROUP PLC: BUSINESS OVERVIEW
FIGURE 34 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021)
11.9 SYNEOS HEALTH
TABLE 137 SYNEOS HEALTH: BUSINESS OVERVIEW
FIGURE 35 SYNEOS HEALTH: COMPANY SNAPSHOT (2021)
11.10 ICON PLC
TABLE 138 ICON: BUSINESS OVERVIEW
FIGURE 36 ICON: COMPANY SNAPSHOT (2021)
11.11 FRONTAGE LABS
TABLE 139 FRONTAGE LABS: BUSINESS OVERVIEW
FIGURE 37 FRONTAGE LABS: COMPANY SNAPSHOT (2021)
11.12 PPD, INC.
TABLE 140 PPD, INC: BUSINESS OVERVIEW
11.13 PAREXEL INTERNATIONAL CORPORATION
TABLE 141 PARAXEL INTERNATIONAL: BUSINESS OVERVIEW
11.14 ALMAC GROUP
TABLE 142 ALMAC GROUP: BUSINESS OVERVIEW
11.15 CELERION
TABLE 143 CELERION: BUSINESS OVERVIEW
11.16 ALTASCIENCES
TABLE 144 ALTASCIENCES: BUSINESS OVERVIEW
11.17 BIOAGILYTIX LABS
TABLE 145 BIOAGILYTIX: BUSINESS OVERVIEW
11.18 LOTUS LABS PVT. LTD.
TABLE 146 LOTUS LABS: BUSINESS OVERVIEW
11.19 LGC LIMITED
TABLE 147 LGC LIMITED: BUSINESS OVERVIEW
11.20 SARTORIUS AG
TABLE 148 SARTORIUS AG: BUSINESS OVERVIEW
11.21 CD BIOSCIENCES INC
TABLE 149 CD BIOSCIENCES INC: BUSINESS OVERVIEW
11.22 ABSORPTION SYSTEMS LLC
TABLE 150 ABSORPTION SYSTEMS LLC: BUSINESS OVERVIEW
11.23 PACE ANALYTICAL
TABLE 151 PACE ANALYTICAL: BUSINESS OVERVIEW
11.24 BIONEEDS INDIA PRIVATE LIMITED
TABLE 152 BIONEEDS INDIA PRIVATE LIMITED: BUSINESS OVERVIEW
11.25 VIPRAGEN BIOSCIENCES
TABLE 153 VIPRAGEN BIOSCIENCES: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 201)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This research study involved the use of extensive secondary sources; directories; databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings. Insights from societies and organizations such as the Biotechnology and Biological Sciences Research Council (BBSRC) and the Centers for Disease Control and Prevention (CDC) were also taken into consideration while estimating the market size.
Secondary Research
Secondary research was mainly used to identify and collect information useful for this extensive, technical, market-oriented, and commercial study of the global bioanalytical testing services market. It was also used to obtain key information about the major players and market classification and segmentation according to industry trends. Primary sources mainly included industry experts from core and related industries, preferred service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative insights.
Primary Research
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the bioanalytical testing services market. Primary sources from the demand side include experts from pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations, and contract research organizations.
A breakdown of the primary respondents for bioanalytical testing services market is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down and bottom-up approaches were used to estimate and validate the size of the global market and various other dependent submarkets. The global bioanalytical testing services market size was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size for market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants.
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.
Objectives of the Study
- To define, describe, analyze, and forecast the size of the bioanalytical testing services market on the basis of product, application, end user, and region.
- To define, describe, and forecast the bioanalytical testing services market by type, application, end user, and region
- To provide detailed information about the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall bioanalytical testing services market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their market shares and core competencies in the bioanalytical testing services market
- To track and analyze competitive developments such as partnerships, collaborations, agreements, acquisitions, and service launches & expansions in the bioanalytical testing services market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific bioanalytical testing services market into Australia, New Zealand, and other countries.
Growth opportunities and latent adjacency in Bioanalytical Testing Services Market
What are the challenges that companies will face in Bioanalytical Testing Services Market?
What are the key trends and future growth of Bioanalytical Testing Services Market?
Which segment to dominate the global Bioanalytical Testing Services industry?
Here are 3 use cases of Bioanalytical Testing Services Market in 2030:
what are the top 3 use cases of Bioanalytical Testing Services Market in 2030?